ライフサイエンスコーパス: ECT

1 ECT combines chemotherapy and electroporation to increas

2 ECT has proven to be effective in the treatment of tumor

3 ECT included three sessions per week for up to 6 weeks,

4 ECT is the most effective treatment for severe depressio

5 ECT occurs at a higher-than-expected rate in patients wi

6 ECT was deemed appropriate but required emergency guardi

7 ECT was performed three times per week for the first 4 w

8 ECT-2, the exchange factor responsible for RhoA activati

9 ECT-2, the guanine nucleotide exchange factor (GEF) requ

10 ECT-2, the guanine nucleotide exchange factor (GEF) that

11 ECT-induced neuroplasticity in the hippocampus and amygd

12 ntre, randomised, parallel-group study in 11 ECT suites serving inpatient and outpatient care setting

13 he kinesin MKLP1/ZEN-4, is known to activate ECT-2, but the underlying mechanism is not understood.

14 ated with right unilateral ultra-brief acute ECT.

15 ase, 70% responded and 47% remitted to acute ECT.

16 Additional ECT after remission (here operationalized as four contin

17 clinical issues and the risks of additional ECT.

18 ECT treatments over 1 month, plus additional ECT as needed, using the Symptom-Titrated, Algorithm-Bas

19 d ECT to 6.6% among individuals administered ECT (risk ratio [RR], 0.54; 95% CI, 0.28-0.81).

20 ted 12.3% among individuals not administered ECT to 6.6% among individuals administered ECT (risk rat

21 l connectivity in the brain before and after ECT treatment.

22 onnectivity was considerably decreased after ECT treatment (P < 0.05, family-wise error-corrected).

23 x and left postcentral gyrus/precuneus after ECT.

24 arly Caenorhabditis elegans embryos, not all ECT-2-dependent functions require CYK-4.

25 Although ECT has been successfully applied in clinical practice f

26 ant response differential was observed among ECT nonresponders (59.6% compared with 34.1%).

27 lafaxine plus lithium, over 24 weeks) and an ECT plus medication arm (four continuation ECT treatment

28 er their second ECT, and after completing an ECT treatment index.

29 Two patients required the postponement of an ECT session because of mild confusion.

30 One group received an ECT series in addition to antidepressants (n = 24); a co

31 ge RP (CNTF3, and CNTF4) studies received an ECT-CNTF implant, designated as "NT-501," in one eye.

32 tivation, the catalytic domains of CYK-4 and ECT-2 directly interact.

33 Patients and assessment and ECT treatment teams were masked to treatment allocation,

34 rTMS was not as effective as ECT, and ECT was substantially more effective for the short-term

35 enzodiazepines, antipsychotics, lithium, and ECT.

36 The basis of the association between SJS and ECT is considered, as well as the role of plausible cont

37 re identified with diagnoses of both SJS and ECT.

38 tify patients with diagnoses of both SJS and ECT.

39 dividual components of chemoreceptor arrays, ECT has revealed the mesoscale information about how the

40 has been to bacterial chemoreceptor arrays, ECT's contributions to this field illustrate well its pa

41 rTMS was not as effective as ECT, and ECT was substantially more effective for the sh

42 Patients were assessed before ECT, after their second ECT, and after completing an ECT

43 ic RhoGEF involves complex formation between ECT-2, centralspindlin and RhoA.

44 se effects of right unilateral and bilateral ECT.

45 east equivalent to moderate-dosage bilateral ECT in efficacy, but retains advantages with respect to

46 l (clozapine group) or a course of bilateral ECT plus clozapine (ECT plus clozapine group).

47 did not differ or was superior to bilateral ECT in efficacy and resulted in less severe amnesia.

48 instead proposed to activate Rho by binding ECT-2.

49 Bitemporal ECT was associated with a lower percent recall of autobi

50 ate-dose (1.5x seizure threshold) bitemporal ECT with high-dose unilateral ECT in real-world practice

51 ble patients, 69 were assigned to bitemporal ECT and 69 to unilateral ECT.

52 ight unilateral ECT is similar to bitemporal ECT but may have fewer cognitive side effects.

53 unilateral ECT is not inferior to bitemporal ECT for depression and may be preferable because of its

54 unilateral ECT was noninferior to bitemporal ECT regarding the 24-item HAM-D scores after the ECT cou

55 TF in the vitreous continuously delivered by ECT implants was 51 months, with CNTF levels statistical

56 thin different brain regions, are induced by ECT, the antidepressant-like effect of ECT in an animal

57 ion of the C. elegans zygote is initiated by ECT-2-dependent cortical flows, which mobilize the anter

58 omyocytes used to construct the cMyBP-C(-/-) ECT had yet to undergo the significant hypertrophic remo

59 In human cells, ECT-2 activity requires its association with CYK-4, whic

60 or a course of bilateral ECT plus clozapine (ECT plus clozapine group).

61 peated-measures modeling was used to compare ECT plus medication and medication alone for efficacy an

62 major depression in hospitals that conducted ECT fell from 70.5% to 44.7%, whereas receipt of ECT whe

63 ereas the percentage of hospitals conducting ECT decreased from 14.8% to 10.6%.

64 ly to receive care from hospitals conducting ECT.

65 bability that the treating hospital conducts ECT fell 34%, whereas probability of receiving ECT was u

66 the probability that their hospital conducts ECT.

67 46) were treated in a hospital that conducts ECT and, if so, received the procedure.

68 phetamine psychosis and may wish to consider ECT in refractory cases.

69 n (here operationalized as four continuation ECT treatments followed by further ECT only as needed) w

70 n ECT plus medication arm (four continuation ECT treatments over 1 month, plus additional ECT as need

71 he efficacy and tolerability of continuation ECT plus medication compared with medication alone in de

72 ithium) or pharmacotherapy plus continuation ECT.

73 assessed whether psychotherapy, continuation ECT, or antidepressant medication is the most efficaciou

74 was significantly less than for conventional ECT with high, fixed current (94-99%).

75 ss intense electric fields than conventional ECT that may be safer; efficacy and side effects should

76 The application of electron cryotomography (ECT) and new methods for fluorescent labelling of peptid

77 Electron cryotomography (ECT) can produce three-dimensional images of biological

78 icroscopy (fLM) and electron cryotomography (ECT) have provided new insight into the bacterial ultras

79 Electron cryotomography (ECT) is an emerging technology that allows thin samples

80 Electron cryotomography (ECT) provides three-dimensional views of macromolecular

81 core, we have used electron cryotomography (ECT) to image infected cells and the viral particles cry

82 Using electron cryotomography (ECT), we find that CdvA polymerizes into helical filamen

83 Phosphoethanolamine cytidylyltransferase (ECT) catalyzes the rate-controlling step in a major path

84 Over the last two decades, ECT has revealed the ultrastructure of cells in unpreced

85 individuals with severe affective disorders, ECT's availability is limited and declining, suggesting

86 ase 1, depressed patients received high-dose ECT (at six times the seizure threshold) three times per

87 nts were randomly assigned to receive either ECT or algorithm-based pharmacological treatment.

88 encourage further investigation to establish ECT's use as first line treatment especially in basocell

89 Here we briefly explain ECT, review its recent contributions to microbiology, an

90 ed by the guanine-nucleotide exchange factor ECT-2, is upstream of both myosin-II activation and diap

91 es model in all patients receiving the first ECT treatment.

92 on in the stimulation focality by 40-53% for ECT and 26% for MST, supporting amplitude individualizat

93 lization as a means of dosing especially for ECT.

94 onventional pulse amplitudes (112-174 mA for ECT and 37.4% of maximum device amplitude for MST).

95 ting the ECT treatment series), referred for ECT as part of their standard clinical care.

96 patients with major depression referred for ECT were randomly assigned to either a 15-day course of

97 er alternative to empirical ST titration for ECT and MST.

98 Thus, large-format ECTs generated from hiPSC-derived cardiac cells may be f

99 delayed verbal recall (HVLT-R-DR) after four ECT treatments, using a Gaussian repeated measures model

100 ocality of stimulation in the brain for four ECT electrode configurations (bilateral, bifrontal, righ

101 tinuation ECT treatments followed by further ECT only as needed) was beneficial in sustaining mood im

102 we show that the mammalian Rho GEF homolog, ECT-2, functions through the conserved RAS/ERK MAP kinas

103 ty can be rescued by activating mutations in ECT-2 or depletion of RGA-3/4, which functions as a conv

104 devices have focused attention on trends in ECT use, but current national data have been unavailable

105 ST was more variable in ECT than in MST.

106 our or more depression treatments (including ECT).

107 nt subgenual cingulate volume and individual ECT response (Montreal Neurological Institute [MNI] coor

108 Increased initial ECT cell number beyond 6 M per construct resulted in red

109 At the initial ECT session, the elicited seizure was followed by an epi

110 We generated mechanically integrated ECT using isolated neonatal mouse cardiac cells derived

111 es derived from hiPSCs and incorporated into ECTs promotes functional maturation and demonstrates myo

112 tive study demonstrated that the intraocular ECT implant has a favorable pharmacokinetic profile for

113 tment gray matter volumes and to investigate ECT-related structural changes.

114 e annual number of inpatient stays involving ECT and proportion of general hospitals conducting the p

115 The annual number of stays involving ECT fell from 12.6 to 7.2/100,000 adult US residents, dr

116 s large-format engineered cardiac tissue (LF-ECT) composed of human induced pluripotent stem cells (h

117 mptom-Titrated, Algorithm-Based Longitudinal ECT [STABLE] algorithm, while continuing venlafaxine plu

118 ients typically require frequent maintenance ECT (mECT), as often as every 5 days, to sustain the imp

119 The CM+EC+MC ECTs implanted onto infarcted, immune tolerant rat heart

120 vitro force measurement showed that CM+EC+MC ECTs possessed preferential electromechanical properties

121 We generated a larger (30 x 30 mm) ME-ECT to confirm scalability.

122 ME-ECTs displayed the lowest dead cell ratio (p < 0.001) an

123 The 6M-ME-ECTs implanted onto 1 week post-infarct immune tolerant

124 We explored multiple 15 x 15 mm ECT geometries using molds with rectangular internal sta

125 among health care professionals about modern ECT technique.

126 Data presented here show mouse ECT to be an efficient and cost-effective platform to st

127 Development of a murine ECT would provide access to many existing models of card

128 Thus, this murine ECT model reveals a contractile phenotype that is specif

129 The murine ECTs produced consistent contractile forces that followe

130 ale; age=56.7 years [SD=14.8]) in a national ECT service with a 6-month follow-up.

131 sion of human cMyBP-C in murine cMyBP-C-null ECT restored contractile properties to levels indistingu

132 cMyBP-C-null ECTs showed characteristic acceleration of contraction k

133 at can polarize the zygote in the absence of ECT-2-dependent cortical flows.

134 contributes to the antidepressant action of ECT and implicate the ability of ECS to induce dendritic

135 The mode of action of ECT has even been ascribed to a "barbaric" form of place

136 Administration of ECT was associated with a reduced 30-day readmission ris

137 we determine the effects of diagnosis and of ECT on global and local variations of hippocampal and am

138 ld exposure in the brain, but this aspect of ECT dosing is largely unexplored.

139 Ketamine augmentation of ECT (five trials encompassing 89 ketamine-treated partic

140 ecision making regarding the availability of ECT.

141 t but functionally related in the context of ECT response.

142 obit model of the association correlation of ECT administration with patient risk of 30-day readmissi

143 rontal cortex (N=24) or a standard course of ECT (N=22).

144 iatric patients after a successful course of ECT (phase 1).

145 issues in the administration of a course of ECT, including the consent process.

146 potential role of these models in dosing of ECT and MST.

147 ed by ECT, the antidepressant-like effect of ECT in an animal model depends on reduction of VTA BDNF

148 on blocked the antidepressant-like effect of ECT.

149 the individual therapeutic effectiveness of ECT.

150 l role in the antidepressant-like effects of ECT and performed a direct comparison between BDNF manip

151 cts of diagnosis and longitudinal effects of ECT for volume and surface-based shape metrics of the ca

152 mation about the population-level effects of ECT is needed.

153 y specific, spatially distributed effects of ECT on regional brain structure in two populations: pati

154 and reduced the cognitive adverse effects of ECT relative to placebo.

155 The efficacy of ECT is substantially increased by the addition of an ant

156 the evidence base supporting the efficacy of ECT to treat severe depression in elderly patients.

157 We also discuss the integration of ECT with other techniques, including lower-resolution fl

158 subgroups, analyses included interactions of ECT with age group, sex, race/ethnicity, and diagnosis g

159 They compared efficacy measures of ECT and algorithm-based pharmacological treatment in tre

160 The mean number of ECT treatments to remission was 7.3 (SD=3.1).

161 manipulations on antidepressant outcomes of ECT were evaluated by the forced swim test and by sucros

162 ification yielded a successful prediction of ECT response, with accuracy rates of 78.3% (18 of 23 pat

163 ral plasticity relating to and predictive of ECT response may point to the mechanisms underlying rapi

164 ngual gyrus were identified as predictors of ECT response, achieving accuracy of 89, 90 and 86% for r

165 ctures in major depression and predictors of ECT-related clinical response.

166 The prevalence of ECT in this population exceeded that in the general popu

167 fell from 70.5% to 44.7%, whereas receipt of ECT where conducted declined from 12.9% to 10.5%.

168 ealed that diagnosis of SJS preceded that of ECT.

169 apine group received an 8-week open trial of ECT (crossover phase).

170 ed, suggesting that CYK-4 is not upstream of ECT-2/Rho activation.

171 The authors examined the use of ECT as an augmentation to clozapine for treatment-refrac

172 determined the impact of cell composition on ECT structural and functional properties.

173 inesis failure due to disruption of CYK-4 or ECT-2 but does not rescue cytokinesis failure due to dis

174 nt-to-treat sample included 39 participants (ECT plus clozapine group, N=20; clozapine group, N=19).

175 Here we aim to predict post-ECT depressive rating changes and remission status using

176 Secondary outcome measures were post-ECT reorientation and safety.

177 ating changes and remission status using pre-ECT gray matter (GM) in 38 MDD patients and validate in

178 y pattern classification was used to predict ECT response by structural MRI that was performed before

179 morphometric measures at baseline predicted ECT-related clinical response.

180 l alignment and higher active stress than PS-ECTs.

181 These results suggest that ultra-brief pulse ECT as a continuation treatment correlates with low sust

182 acy studies, using thrice-weekly brief-pulse ECT, reported that high-dose (6x seizure threshold) righ

183 course of right unilateral ultrabrief pulse ECT, augmented with venlafaxine.

184 course of right unilateral ultrabrief pulse ECT, combined with open-label venlafaxine at seven acade

185 Right unilateral ultrabrief pulse ECT, combined with venlafaxine, is a rapidly acting and

186 9 patients from the clozapine group received ECT in the crossover phase.

187 T fell 34%, whereas probability of receiving ECT was unchanged for patients treated in facilities tha

188 C. elegans zygote is initiated by redundant ECT-2- and PAR-2-dependent mechanisms that lower PAR-3 l

189 None of the patients required ECT.

190 cytokinesis, RhoA is activated by the RhoGEF ECT-2.

191 e of adjunctive low-dose ketamine in routine ECT treatment.

192 three times: prior to ECT, after the second ECT session, and within 1 week of completing the ECT tre

193 were assessed before ECT, after their second ECT, and after completing an ECT treatment index.

194 The patient responded to eight subsequent ECT sessions administered with rocuronium, a nondepolari

195 eatment to sustain response after successful ECT in MDD patients.

196 Another report (N=34) described successful ECT treatment.

197 As such, ECT is beginning to deliver long-awaited insight into th

198 of catatonia and address issues surrounding ECT, cardiac effects, use of muscle relaxants, and the c

199 a weaker and more focal electric field than ECT; however, the pulse amplitude is not individualized

200 le to cap coil MST (23%), demonstrating that ECT with a low current amplitude and focal electrode pla

201 Importantly, we found that ECT caused a robust reduction in VTA BDNF levels.

202 This raises the possibility that ECT might be effective in the treatment of PTSD, a disea

203 We report that ECT-2-mediated RhoA activation depends on the ability of

204 ixed-effects modeling analysis revealed that ECT was significantly more effective than algorithm-base

205 Our results show that ECT has lasting effects on the functional architecture o

206 A recent study has shown that ECT is also effective in reducing both depressive and po

207 Results support that ECT elicits structural plasticity in the dorsal and vent

208 regarding the 24-item HAM-D scores after the ECT course (mean difference=1.08 points in favor of unil

209 ression Rating Scale (HAM-D) score after the ECT course; the prespecified noninferiority margin was 4

210 session, and within 1 week of completing the ECT treatment series), referred for ECT as part of their

211 monstrate that this mutation facilitates the ECT in Escherichia coli SecA and triggers it completely

212 e 6-week treatment period were lower for the ECT group than for the pharmacological treatment group:

213 esponse rate was significantly higher in the ECT group than in the group that received algorithm-base

214 Significantly more patients in the ECT plus medication group were rated "not ill at all" on

215 aled a increase in hippocampal volume in the ECT sample (MNI coordinates x = -28, y = -9, z = -18; Z

216 One participant in the ECT sample was excluded from the analysis, leaving 67 pa

217 acy rates of 78.3% (18 of 23 patients in the ECT sample) and sensitivity rates of 100% (13 of 13 who

218 onse rates of 65% in the CBT-arm, 28% in the ECT-arm, and 33% in the MED-arm.

219 onse rates of 77% in the CBT-arm, 40% in the ECT-arm, and 44% in the MED-arm.

220 10-fold increase in triacylglycerols in the ECT-deficient hepatocytes that became engorged with lipi

221 The molecular species of PtdEtn in the ECT-deficient livers were significantly altered compared

222 s' g=0.933) but not at the conclusion of the ECT course.

223 Hepatocyte-specific deletion of the ECT gene in mice resulted in normal appearing animals wi

224 The absence of the ECT pathway for diacylglycerol utilization at the endopl

225 Fifty percent of the ECT plus clozapine patients met the response criterion.

226 ase in entropy observed in the course of the ECT, hydrogen-deuterium exchange mass spectrometry demon

227 In reviewing the ECT complication, it appeared that muscle damage due to

228 T) using single pulses delivered through the ECT electrodes or MST coil.

229 to quantitatively identify and validate the ECT treatment biomarkers using multi-site GM data.

230 At 24 weeks, the ECT plus medication group had statistically significantl

231 to the anaesthetic for the duration of their ECT course.

232 Electroconvulsive therapy (ECT) at conventional current amplitudes (800-900 mA) is

233 We have found electroconvulsive therapy (ECT) can produce life-changing results, with more than 9

234 ultrabrief pulse electroconvulsive therapy (ECT) combined with venlafaxine for the treatment of geri

235 ral regulation of electroconvulsive therapy (ECT) devices have focused attention on trends in ECT use

236 Electroconvulsive therapy (ECT) elicits a rapid and robust clinical response in pat

237 erning the use of electroconvulsive therapy (ECT) for psychiatric disorders stemming from a lack of i

238 rent amplitude in electroconvulsive therapy (ECT) has been proposed as a means to produce stimulation

239 Electroconvulsive therapy (ECT) has been successfully used in the treatment of depr

240 cation for use of electroconvulsive therapy (ECT) in major depression.

241 Electroconvulsive therapy (ECT) is a robust and rapidly acting treatment for severe

242 Although electroconvulsive therapy (ECT) is considered the most efficacious treatment availa

243 The use of electroconvulsive therapy (ECT) is limited by concerns about its cognitive adverse

244 Electroconvulsive therapy (ECT) is one of the most effective treatments for severe

245 Electroconvulsive therapy (ECT) is regarded by many clinicians as the most effectiv

246 Although electroconvulsive therapy (ECT) is the most effective acute antidepressant interven

247 To date, electroconvulsive therapy (ECT) is the most potent treatment in severe depression.

248 onded promptly to electroconvulsive therapy (ECT) on two separate occasions: on initial presentation

249 clinical effects, electroconvulsive therapy (ECT) represents an optimal model to develop and test tre

250 s associated with electroconvulsive therapy (ECT), a highly effective and commonly used antidepressan

251 n, in the form of electroconvulsive therapy (ECT), has long been a gold standard treatment for depres

252 Electroconvulsive therapy (ECT), which has been in use for 75 years, is an importan

253 atments including electroconvulsive therapy (ECT).

254 ulse continuation electroconvulsive therapy (ECT-arm), or no add-on therapy (MED-arm).

255 d thrombin time (dTT), ecarin clotting time (ECT), activated partial thromboplastin time (aPTT), and

256 Current engineered cardiac tissue (ECT) models use cells derived from either rat or chick h

257 We generated engineered cardiac tissues (ECTs) from three cellular compositions of cardiomyocytes

258 bipolar disorders respond differentially to ECT and the associated local brain-volume changes, which

259 c seizure therapy (MST), or modifications to ECT.

260 stopping antidepressant medications prior to ECT derived from studies in the 1960s and 1970s in nonre

261 ssion (N = 43, scanned three times: prior to ECT, after the second ECT session, and within 1 week of

262 ew the basic and clinical science related to ECT's mechanism of action and discuss clinical issues in

263 ity rates of 100% (13 of 13 who responded to ECT).

264 relate to or predict therapeutic response to ECT is unknown.

265 arkers that accurately predict a response to ECT remain unidentified.

266 shape metrics predicted overall response to ECT with up to 89% accuracy.

267 among patients with a history of response to ECT, those in the adjunctive VNS group had a significant

268 lated endothermic conformational transition (ECT) believed to involve similar structural mechanics to

269 ls indistinguishable from those of wild-type ECT.

270 86 of the 162691 inpatients (1.5%) underwent ECT during their index admission.

271 Twenty-five patients underwent ECT for the treatment of non-melanoma head and neck canc

272 ld) bitemporal ECT with high-dose unilateral ECT in real-world practice.

273 Twice-weekly high-dose unilateral ECT is not inferior to bitemporal ECT for depression and

274 High-dose unilateral ECT was noninferior to bitemporal ECT regarding the 24-i

275 signed to bitemporal or high-dose unilateral ECT.

276 orientation was quicker following unilateral ECT (median=19.1 minutes versus 26.4 minutes).

277 ifference=1.08 points in favor of unilateral ECT [95% CI=-1.67 to 3.84]).

278 High-dosage right unilateral ECT did not differ or was superior to bilateral ECT in e

279 dose (6x seizure threshold) right unilateral ECT is similar to bitemporal ECT but may have fewer cogn

280 ality of amplitude-titrated right-unilateral ECT (25%) was comparable to cap coil MST (23%), demonstr

281 High-dose, right-sided, unilateral ECT is at least equivalent to moderate-dosage bilateral

282 igned to bitemporal ECT and 69 to unilateral ECT.

283 complex in a physiological context, we used ECT to image the archaeon Sulfolobus acidocaldarius and

284 heva et al. examined sporulating cells using ECT and fluorescence microscopy to demonstrate the conti

285 ombined visualization of peptidoglycan using ECT with molecular modelling of three proposed arrangeme

286 erential electromechanical properties versus ECTs without vascular cells indicating that incorporatio

287 strumental variable used in the analysis was ECT prevalence in the prior calendar year at the treatin

288 Here, we show that whereas ECT increased hippocampal BDNF expression, induction of

289 To examine whether ECT's association with readmissions was heterogeneous ac

290 While ECT may prove to be an effective treatment for certain s

291 t an illustrative case of a patient for whom ECT is indicated.

292 Significantly larger associations with ECT on readmission risk were found for men compared with

293 The augmentation of clozapine with ECT is a safe and effective treatment option.

294 mpal and the amygdala volumes increased with ECT (p < .001) and in relation to symptom improvement (p

295 ering the glutamate antagonist ketamine with ECT might alleviate cognitive adverse effects and accele

296 n left putamen volume (P<0.03) occurred with ECT.

297 d trial to test the equivalence of rTMS with ECT.

298 amplitude required to induce a seizure with ECT (bilateral, right unilateral, bifrontal, and frontom

299 To examine whether inpatient treatment with ECT is associated with a reduction in 30-day psychiatric

300 be associated with successful treatment with ECT.